Martin Sadowski, MD
Neurology · New York, NYNPI 1407840127
Payments from drug & device makers
Across 274 payments — averaging $19,603 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$1.6M
- Eisai Inc.$1.6M
- Eli Lilly$941K
- Novartis$675K
- Janssen Research & Development, LLC$440K
- Novo Nordisk AS$40K
- plus $23K from 7 others
Across 1 payment — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$50
What the payments were for
- Consulting fees$48,55885%
- Travel & lodging$7,31413%
- Food & beverage$1,4713%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 22 | $1,644,244 |
| Eisai Inc. | 102 | $1,608,170 |
| Eli Lilly | 31 | $940,574 |
| Novartis | 7 | $675,466 |
| Janssen Research & Development, LLC | 76 | $439,754 |
| Novo Nordisk AS | 10 | $40,304 |
| Axsome Therapeutics, Inc. | 7 | $7,400 |
| Merck | 4 | $7,312 |
| E.r. Squibb & Sons, L.L.C. | 2 | $4,305 |
| Genentech, Inc. | 1 | $2,070 |
| Alnylam Pharmaceuticals Inc. | 9 | $1,039 |
| BD | 1 | $623 |
| Lilly USA, LLC | 2 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$20,240
How this compares
$5,371,326 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Galantamine ErGalantamine Hbr | 157 | $15,241 |
| Rivastigmine | 68 | $9,876 |
| Memantine Hcl ErMemantine Hcl | 61 | $8,792 |
| Memantine Hcl | 180 | $5,595 |
| RivastigmineRivastigmine Tartrate | 16 | $766 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 32 | $627 |
| Gabapentin | 26 | $401 |
| Levetiracetam | 13 | $357 |
| Escitalopram Oxalate | 22 | $323 |
| Donepezil Hcl | 28 | $314 |
| Quetiapine Fumarate | 17 | $249 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 11 | $30 |
Paid to pharmacies, not to this prescriber.
Other neurology in New York
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Lawrence HonigNew York$4.9M
- Sheng-Han KuoNew York$3.2M
- Stephen KriegerNew York$3.1M
- Thomas KaleyNew York$2.9M
- Aaron MillerNew York$2.8M
- Andrew LassmanNew York$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.